The biotech IPO outlook is strong, say experts
Biotech CEOs weathering a lean investment market got some good news from a panel of experts on Feb. 27. Following a couple of painfully […]
The biotech IPO outlook is strong, say experts Read More »
BIO Events
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
Biotech investment is scarce, but still available, experts tell CEOs
Even in this challenging market, biotechnology firms are attracting investment and building capital, but they need more than just a great innovation. They also
Biotech investment is scarce, but still available, experts tell CEOs Read More »
What biotech companies should know about M&A in down markets
Mergers and acquisitions (M&A) are important elements of the biotech industry, especially for early-stage fundraising and bringing new drugs and treatments to the market.
What biotech companies should know about M&A in down markets Read More »
The future of next-generation obesity drugs
The metabolic field is the hottest biotech therapeutic area of the year (and likely to continue beyond). In the context of a difficult couple
The future of next-generation obesity drugs Read More »
Drug developers and investors need to join AI revolution, panel says
Artificial intelligence and machine learning have boosted drug development and enhanced the value of biotech firms for years, but investors and companies need to
Drug developers and investors need to join AI revolution, panel says Read More »
What policy biotech should be watching this election year
The biotech industry must constantly navigate the ins and outs of Beltway politics. During an election year, the need to anticipate and plan for
What policy biotech should be watching this election year Read More »
CEOs explore challenges and opportunities in vaccine pipeline
The Biotechnology Innovations Organization (BIO) report, The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases, on January 25, 2024, found that
CEOs explore challenges and opportunities in vaccine pipeline Read More »
CEOs say market must keep up with the science of gene therapies
The science of gene therapies is progressing at a remarkable pace, but if these medicines are going to reach patients, trends in investment and
CEOs say market must keep up with the science of gene therapies Read More »
NYCEDC seeks private-sector life sciences anchor tenant at SPARC Kips Bay
The New York City Economic Development Corporation (NYCEDC) announced on February 26 that it’s seeking a private-sector anchor tenant for the Science Park and
NYCEDC seeks private-sector life sciences anchor tenant at SPARC Kips Bay Read More »
When Medicine Stops Saving Us: The Antimicrobial Resistance Crisis
“If you want to go fast, go alone,” said Interim Dean of UCLA’s Division of Social Sciences, Abel Valenzuela Jr., giving opening remarks at
When Medicine Stops Saving Us: The Antimicrobial Resistance Crisis Read More »